国际标准期刊号: 2161-0711

社区医学与健康教育

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • Genamics 期刊搜索
  • 安全点亮
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Removing the User Fees for the Under-Fives' Simple Malaria Treatment in Cameroon: Effect on the Health Services Utilization

Isidore Sieleunou, Emmanuel Betsi, Jean Christian Kouontchou, Alain Takeu Nguela and Habakkuk Azinyui Yumo

Background: Access to free diagnoses and treatments has been shown to be a major determinant in malaria control. The Cameroonian government launched in February 2011 the exemption of the under-fives' simple malaria treatment policy. This study aimed at assessing the main effect of the policy on services utilization. Methods: A concurrent mixed-method research using time series data collected in July 2011 and April 2012, and qualitative data collected in April 2012 was conducted. Content analysis was used for the qualitative data. For the quantitative data, a proxy was used to measure living standards by calculating a composite index using principal component analysis. Results: General outpatients consultations and of the under-five (U5) increased to about 10% during the year 2011 compared to the year 2010 (before the policy). The average number of consultations for simple malaria cases in children U5 increased in the months following the launch of the policy then started declining from September 2011. The proportion of U5 who was exempted from payment of drugs increased from 19.6% to 32.9% at 4 and 12 months after the implementation of the policy. In contrast there was no effect in reducing inequalities among socioeconomic groups: the rural and lowest socio-economic households benefit less from the exemption measure (RR respectively 2.7, 1.6). Two thirds of U5 who used health services for uncomplicated malaria paid on average 2940 FCFA (6 $USA) for the treatment. The major part of this cost was made on the acquisition of artemisinin combination therapy (1680 FCFA/3.5 $USA).